Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

 Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Shots:

  • Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020.
  • The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for multiple diseases, including cancer
  • STI-1499 is expected to be evaluated in ICU patients to ensure safety and potentially allow a preliminary look at efficacy. In vitro results demonstrated STI-1499’s ability to completely neutralize SARS-CoV-2 infection @low doses, making it lead candidate for potential treatment against COVID-19

Click here to read full press release/ article | Ref: Sorrento | Image: SmartPharm

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post